FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552678312> ?p ?o ?g. }

• W2552678312 abstract "Introduction Pre‐treatment HIV drug resistance (PDR) is an increasing problem in sub‐Saharan Africa. Children are an especially vulnerable population to develop PDR given that paediatric second‐line treatment options are limited. Although monitoring of PDR is important, data on the paediatric prevalence in sub‐Saharan Africa and its consequences for treatment outcomes are scarce. We designed a prospective paediatric cohort study to document the prevalence of PDR and its effect on subsequent treatment failure in Nigeria, the country with the second highest number of HIV‐infected children in the world. Methods HIV‐1‐infected children ≤12 years, who had not been exposed to drugs for the prevention of mother‐to‐child transmission (PMTCT), were enrolled between 2012 and 2013, and followed up for 24 months in Lagos, Nigeria. Pre‐antiretroviral treatment (ART) population‐based pol genotypic testing and six‐monthly viral load (VL) testing were performed. Logistic regression analysis was used to assess the effect of PDR (World Health Organization (WHO) list for transmitted drug resistance) on subsequent treatment failure (two consecutive VL measurements >1000 cps/ml or death). Results Of the total 82 PMTCT‐naïve children, 13 (15.9%) had PDR. All 13 children harboured non‐nucleoside reverse transcriptase inhibitor (NNRTI) mutations, of whom seven also had nucleoside reverse transcriptase inhibitor resistance. After 24 months, 33% had experienced treatment failure. Treatment failure was associated with PDR and a higher log VL before treatment initiation (adjusted odds ratio (aOR) 7.53 (95%CI 1.61–35.15) and 2.85 (95%CI 1.04–7.78), respectively). Discussion PDR was present in one out of six Nigerian children. These high numbers corroborate with recent findings in other African countries. The presence of PDR was relevant as it was the strongest predictor of first‐line treatment failure. Conclusions Our findings stress the importance of implementing fully active regimens in children living with HIV. This includes the implementation of protease inhibitor (PI)‐based first‐line ART, as is recommended by the WHO for all HIV‐infected children <3 years of age. Overcoming practical barriers to implement PI‐based regimens is essential to ensure optimal treatment for HIV‐infected children in sub‐Saharan Africa. In countries where individual VL or resistance testing is not possible, more attention should be given to paediatric PDR surveys." @default.
• W2552678312 created "2016-11-30" @default.
• W2552678312 creator A5003302321 @default.
• W2552678312 creator A5006363203 @default.
• W2552678312 creator A5017569833 @default.
• W2552678312 creator A5021025618 @default.
• W2552678312 creator A5031077871 @default.
• W2552678312 creator A5036271514 @default.
• W2552678312 creator A5039441078 @default.
• W2552678312 creator A5047657659 @default.
• W2552678312 creator A5054490440 @default.
• W2552678312 creator A5061809416 @default.
• W2552678312 creator A5065647297 @default.
• W2552678312 creator A5089133309 @default.
• W2552678312 date "2016-01-01" @default.
• W2552678312 modified "2023-10-15" @default.
• W2552678312 title "High levels of pre‐treatment HIV drug resistance and treatment failure in Nigerian children" @default.
• W2552678312 cites W1091871359 @default.
• W2552678312 cites W1969028669 @default.
• W2552678312 cites W1983504410 @default.
• W2552678312 cites W1991186486 @default.
• W2552678312 cites W1998805206 @default.
• W2552678312 cites W2002432974 @default.
• W2552678312 cites W2058201602 @default.
• W2552678312 cites W2063585057 @default.
• W2552678312 cites W2068974703 @default.
• W2552678312 cites W2088020479 @default.
• W2552678312 cites W2090570409 @default.
• W2552678312 cites W2103414045 @default.
• W2552678312 cites W2105712999 @default.
• W2552678312 cites W2109046728 @default.
• W2552678312 cites W2117528681 @default.
• W2552678312 cites W2121717451 @default.
• W2552678312 cites W2139311359 @default.
• W2552678312 cites W2146808131 @default.
• W2552678312 cites W2148684707 @default.
• W2552678312 cites W2152896082 @default.
• W2552678312 cites W2154164013 @default.
• W2552678312 cites W2161221967 @default.
• W2552678312 cites W2167796366 @default.
• W2552678312 cites W2169784150 @default.
• W2552678312 cites W2170463669 @default.
• W2552678312 cites W2201163923 @default.
• W2552678312 doi "https://doi.org/10.7448/ias.19.1.21140" @default.
• W2552678312 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5106466" @default.
• W2552678312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27836020" @default.
• W2552678312 hasPublicationYear "2016" @default.
• W2552678312 type Work @default.
• W2552678312 sameAs 2552678312 @default.
• W2552678312 citedByCount "32" @default.
• W2552678312 countsByYear W25526783122017 @default.
• W2552678312 countsByYear W25526783122018 @default.
• W2552678312 countsByYear W25526783122019 @default.
• W2552678312 countsByYear W25526783122020 @default.
• W2552678312 countsByYear W25526783122021 @default.
• W2552678312 countsByYear W25526783122022 @default.
• W2552678312 countsByYear W25526783122023 @default.
• W2552678312 crossrefType "journal-article" @default.
• W2552678312 hasAuthorship W2552678312A5003302321 @default.
• W2552678312 hasAuthorship W2552678312A5006363203 @default.
• W2552678312 hasAuthorship W2552678312A5017569833 @default.
• W2552678312 hasAuthorship W2552678312A5021025618 @default.
• W2552678312 hasAuthorship W2552678312A5031077871 @default.
• W2552678312 hasAuthorship W2552678312A5036271514 @default.
• W2552678312 hasAuthorship W2552678312A5039441078 @default.
• W2552678312 hasAuthorship W2552678312A5047657659 @default.
• W2552678312 hasAuthorship W2552678312A5054490440 @default.
• W2552678312 hasAuthorship W2552678312A5061809416 @default.
• W2552678312 hasAuthorship W2552678312A5065647297 @default.
• W2552678312 hasAuthorship W2552678312A5089133309 @default.
• W2552678312 hasBestOaLocation W25526783121 @default.
• W2552678312 hasConcept C114851261 @default.
• W2552678312 hasConcept C119599485 @default.
• W2552678312 hasConcept C126322002 @default.
• W2552678312 hasConcept C127413603 @default.
• W2552678312 hasConcept C142462285 @default.
• W2552678312 hasConcept C156957248 @default.
• W2552678312 hasConcept C187212893 @default.
• W2552678312 hasConcept C203014093 @default.
• W2552678312 hasConcept C2778451633 @default.
• W2552678312 hasConcept C2908647359 @default.
• W2552678312 hasConcept C2993143319 @default.
• W2552678312 hasConcept C3013748606 @default.
• W2552678312 hasConcept C71924100 @default.
• W2552678312 hasConcept C761482 @default.
• W2552678312 hasConcept C86803240 @default.
• W2552678312 hasConcept C89423630 @default.
• W2552678312 hasConcept C99454951 @default.
• W2552678312 hasConceptScore W2552678312C114851261 @default.
• W2552678312 hasConceptScore W2552678312C119599485 @default.
• W2552678312 hasConceptScore W2552678312C126322002 @default.
• W2552678312 hasConceptScore W2552678312C127413603 @default.
• W2552678312 hasConceptScore W2552678312C142462285 @default.
• W2552678312 hasConceptScore W2552678312C156957248 @default.
• W2552678312 hasConceptScore W2552678312C187212893 @default.
• W2552678312 hasConceptScore W2552678312C203014093 @default.
• W2552678312 hasConceptScore W2552678312C2778451633 @default.
• W2552678312 hasConceptScore W2552678312C2908647359 @default.
• W2552678312 hasConceptScore W2552678312C2993143319 @default.
• W2552678312 hasConceptScore W2552678312C3013748606 @default.

• next